KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $955970.0.

  • Inovio Pharmaceuticals' Accumulated Expenses fell 7874.0% to $955970.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $955970.0, marking a year-over-year decrease of 7874.0%. This contributed to the annual value of $2.0 million for FY2024, which is 1452.29% down from last year.
  • Inovio Pharmaceuticals' Accumulated Expenses amounted to $955970.0 in Q3 2025, which was down 7874.0% from $1.5 million recorded in Q2 2025.
  • Inovio Pharmaceuticals' 5-year Accumulated Expenses high stood at $13.6 million for Q3 2021, and its period low was $955970.0 during Q3 2025.
  • Moreover, its 5-year median value for Accumulated Expenses was $5.8 million (2023), whereas its average is $6.7 million.
  • Per our database at Business Quant, Inovio Pharmaceuticals' Accumulated Expenses soared by 13315.19% in 2021 and then plummeted by 7874.0% in 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Accumulated Expenses (Quarter) stood at $10.3 million in 2021, then rose by 2.59% to $10.6 million in 2022, then plummeted by 77.67% to $2.4 million in 2023, then dropped by 14.52% to $2.0 million in 2024, then tumbled by 52.72% to $955970.0 in 2025.
  • Its last three reported values are $955970.0 in Q3 2025, $1.5 million for Q2 2025, and $1.8 million during Q1 2025.